Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Recce

Recce

## Sitemaps

- [XML Sitemap](https://www.recce.com.au/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Recce advances anti-infective gel to Phase III trial for diabetic foot infections in Australia](https://www.recce.com.au/recce-advances-anti-infective-gel-to-phase-iii-trial-for-diabetic-foot-infections-in-australia/)
- [New diabetic foot infection treatment could reach Morocco under regional deal](https://www.recce.com.au/new-diabetic-foot-infection-treatment-could-reach-morocco-under-regional-deal/)
- [Recce signs major MENA 10-year licensing deal](https://www.recce.com.au/recce-signs-major-mena-10-year-licensing-deal/)
- [ASX healthcare innovators target costly surgical complications and repeat procedures](https://www.recce.com.au/asx-healthcare-innovators-target-costly-surgical-complications-and-repeat-procedures/)
- [Recce clears regulatory inspection for Phase III DFI trial in Indonesia](https://www.recce.com.au/recce-clears-regulatory-inspection-for-phase-iii-dfi-trial-in-indonesia/)
- [No more tears as Recce takes on antibiotic superbug crisis](https://www.recce.com.au/no-more-tears-as-recce-takes-on-antibiotic-superbug-crisis/)
- [Inside Biotech: Recce Pharmaceuticals advances late-stage push in antibiotic resistance fight](https://www.recce.com.au/inside-biotech-recce-pharmaceuticals-advances-late-stage-push-in-antibiotic-resistance-fight/)
- [Biocurious: US military enlists Aussie biotechs in the germ warfare battle](https://www.recce.com.au/biocurious-us-military-enlists-aussie-biotechs-in-the-germ-warfare-battle-2/)
- [Recce lands Brazil patent as global anti-infectives footprint expands](https://www.recce.com.au/biocurious-us-military-enlists-aussie-biotechs-in-the-germ-warfare-battle/)
- [The world is running out of antibiotics. New research could make old ones work again](https://www.recce.com.au/the-world-is-running-out-of-antibiotics-new-research-could-make-old-ones-work-again/)
- [US Army backs Recce’s synthetic antibiotic for burns](https://www.recce.com.au/us-army-backs-recces-synthetic-antibiotic-for-burns/)
- [Break it Down: Recce expands US Army research deals to fight deadly pathogens](https://www.recce.com.au/break-it-down-recce-expands-us-army-research-deals-to-fight-deadly-pathogens/)
- [Executive Edge: James Graham on Recce’s fight against superbugs](https://www.recce.com.au/executive-edge-james-graham-on-recces-fight-against-superbugs/)
- [Recce expands US government collaborations](https://www.recce.com.au/recce-expands-us-government-collaborations/)
- [2025 Wrapped: Recce Pharmaceuticals wraps up a healthy past 12 months](https://www.recce.com.au/2025-wrapped-recce-pharmaceuticals-wraps-up-a-healthy-past-12-months/)
- [Break it Down: Recce in pole position for mega tax rebate](https://www.recce.com.au/break-it-down-recce-in-pole-position-for-mega-tax-rebate/)
- [R327 shows strong efficacy in lung infection trial](https://www.recce.com.au/r327-shows-strong-efficacy-in-lung-infection-trial/)
- [WHO 2025 Antibacterial Pipeline Report](https://www.recce.com.au/who-2025-antibacterial-pipeline-report/)
- [Recce Pharmaceuticals Targets Diabetic Foot Infections With First-in-Class Synthetic Anti-Infective](https://www.recce.com.au/recce-pharmaceuticals-targets-diabetic-foot-infections-with-first-in-class-synthetic-anti-infective/)
- [Recce's RECCE® 327 Topical Gel targets superbugs, speeds wound healing](https://www.recce.com.au/recces-recce-327-topical-gel-targets-superbugs-speeds-wound-healing/)
- [RECCE® 327 Topical Gel shows strong preclinical results](https://www.recce.com.au/recce-327-topical-gel-shows-strong-preclinical-results/)
- [Recce secures $30m debt facility to support Phase III trials](https://www.recce.com.au/recce-secures-30m-debt-facility-to-support-phase-iii-trials/)
- [Break it Down: Recce partners with the US Army](https://www.recce.com.au/break-it-down-recce-partners-with-the-us-army/)
- [Recce to expand Phase II trial for diabetic foot infections](https://www.recce.com.au/recce-to-expand-phase-ii-trial-for-diabetic-foot-infections/)
- [Recce raising up to $15.8m for Phase III trials](https://www.recce.com.au/recce-raising-up-to-15-8m-for-phase-iii-trials/)
- [Australian biotech points to potential superbug use as gel treats skin infections in phase 2 trial](https://www.recce.com.au/australian-biotech-points-to-potential-superbug-use-as-gel-treats-skin-infections-in-phase-2-trial/)
- [Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial](https://www.recce.com.au/biocurious-for-recce-our-near-neighbour-was-the-obvious-place-to-launch-a-diabetes-related-trial/)
- [Synthetic Gel Shows Utility Across ABSSSI, Company Sees Other Indications](https://www.recce.com.au/synthetic-gel-shows-utility-across-absssi-company-sees-other-indications/)
- [Recce soars on phase II skin infection trial results](https://www.recce.com.au/recce-soars-on-phase-ii-skin-infection-trial-results/)
- [Recce Pharmaceuticals doses all patients in phase II skin infection trial](https://www.recce.com.au/recce-pharmaceuticals-doses-all-patients-in-phase-ii-skin-infection-trial/)
- [Recce Pharmaceuticals doses all patients in Phase 2 clinical trial of RECCE® 327 topical gel for skin infections](https://www.recce.com.au/recce-pharmaceuticals-doses-all-patients-in-phase-2-clinical-trial-of-recce-327-topical-gel-for-skin-infections/)
- [Recce gets Indonesian nod for phase III trial of diabetic foot infection treatment](https://www.recce.com.au/recce-gets-indonesian-nod-for-phase-iii-trial-of-diabetic-foot-infection-treatment/)
- [Complete patent protection for 2 Recce anti-infective treatments](https://www.recce.com.au/complete-patent-protection-for-2-recce-anti-infective-treatments/)
- [Recce green lit to begin dosing in registrational Phase 3 trial for diabetic foot infections](https://www.recce.com.au/recce-green-lit-to-begin-dosing-in-registrational-phase-3-trial-for-diabetic-foot-infections/)
- [From No More Tears to no more superbug fears](https://www.recce.com.au/from-no-more-tears-to-no-more-superbug-fears/)
- [Here’s why you’ll see more ASX biotechs focus on Asia in the years ahead!](https://www.recce.com.au/heres-why-youll-see-more-asx-biotechs-focus-on-asia-in-the-years-ahead/)
- [Local Pharma Fights Superbugs](https://www.recce.com.au/local-pharma-fights-superbugs/)
- [Recce’s Phase 2 trial for skin infections hits midway recruitment milestone](https://www.recce.com.au/recces-phase-2-trial-for-skin-infections-hits-midway-recruitment-milestone/)
- [Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger](https://www.recce.com.au/recce-eyes-indonesia-for-novel-anti-infective-as-indo-aus-ties-grow-stronger/)
- [Recce Pharmaceuticals (ASX:RCE) granted notification of intent for Australian patent](https://www.recce.com.au/recce-pharmaceuticals-asxrce-granted-notification-of-intent-for-australian-patent/)
- [Proactive Investors - The smart money in medicine: the silent pandemic](https://www.recce.com.au/proactive-investors-the-smart-money-in-medicine-the-silent-pandemic/) - Recce Pharmaceuticals is working on a solution.
- [Recce tapping European investor interest](https://www.recce.com.au/recce-tapping-european-investor-interest/) - Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
- [For this pharma boss, fishing is an experience in positivity](https://www.recce.com.au/for-this-pharma-boss-fishing-is-an-experience-in-positivity/)
- [Recce Pharmaceuticals boosts finances with A$6.21 million in R&D rebate payments](https://www.recce.com.au/recce-pharmaceuticals-boosts-finances-with-a6-21-million-in-rd-rebate-payments/)
- [Recce Pharmaceuticals (ASX:RCE) selects CMAX for phase I/II UTI clinical trial](https://www.recce.com.au/recce-pharmaceuticals-asxrce-selects-cmax-for-phase-i-ii-uti-clinical-trial/)
- [Recce Pharmaceuticals (ASX:RCE) receives ‘intent to grant’ Patent Family 4 for anti-infectives](https://www.recce.com.au/recce-pharmaceuticals-asxrce-receives-intent-to-grant-patent-family-4-for-anti-infectives/)
- [Recce tapping European investor interest](https://www.recce.com.au/recce-tapping-european-investor-interest-2/) - Recce listed on the Frankfurt Stock Exchange and is working with German asset manager DGWA as it embarks on a global superbug-fighting strategy.
- [AusBiotech Journal 2021 Vol 31](https://www.recce.com.au/ausbiotech-journal-2021-vol-31/) - A REVOLUTIONARY APPROACH against antimicrobial resistance
- [PharmaShots Interview w Recce CEO James Graham](https://www.recce.com.au/pharmashots-interview-w-recce-ceo-james-graham/) - James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds.
- [AusBiotech Journal 2020 Vol 30](https://www.recce.com.au/ausbiotech-journal-2020-vol-30/) - ADVANCING THE ‘ARMS RACE’ against antibiotic-resistant superbugs
- [AusBiotech Journal 2020 Vol 30](https://www.recce.com.au/ausbiotech-journal-2020-vol-30-2/) - A NEW CLASS OF ANTIBIOTICS
- [H.C. Wainwright Global Life Sciences Conference](https://www.recce.com.au/h-c-wainwright-global-life-sciences-conference/) - Click here for full Press Release and Presentation
- [Pharmafiles 2020: Synthetic Anti-Infectives](https://www.recce.com.au/pharmafiles-2020-synthetic-anti-infectives/) - AMR is a ticking time bomb argues Recce CEO James Graham...
- [The Australian - Research Special Report 2020](https://www.recce.com.au/the-australian-research-special-report-2020/) - A revolutionary approach to medicine: synthetic anti-Infectives Anti-infectives are used as our frontline treatment for everyday and life threatening bacteria and viral infections…
- [Coronavirus crisis](https://www.recce.com.au/coronavirus-crisis/) - Recce Pharmaceuticals is among dozens of WA-founded biotech companies that are making serious waves in the medical research sector, with COVID-19 the latest disease in its sights...
- [Nature Biopharma](https://www.recce.com.au/nature-biopharma/) - New class of synthetic antibiotics set to tackle superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
- [Fighting Antibiotic Resistance](https://www.recce.com.au/fighting-antibiotic-resistance/) - The world needs new classes of antibiotics Antibiotics The world needs new classes of antibiotics Antibiotics are used as our frontline treatment...
- [BioWorld](https://www.recce.com.au/bioworld/) - Recce nears clinic with ‘master key’ antibiotic to take on superbugs PERTH, Australia – A new class of synthetic antibiotics with broad-spectrum activity is being developed by Sydney-based...
- [The Australian](https://www.recce.com.au/the-australian/) - Australia’s Recce strives for immune-proof super-antibiotic Introductory offers to be billed as follows: The Australian Digital Subscription costs 50c per day, billed monthly (min cost up...
- [The West Australian](https://www.recce.com.au/the-west-australian/) - WA tests synthetic antibiotic A Perth-based pharmaceutical research company is a step closer to developing a new class of synthetic antibiotics to overcome superbugs. Recce Limited has started ...
- [S&P Global](https://www.recce.com.au/sp-global/) - Small companies play big role in search for superbug killers Superbugs are quickly becoming a top health concern, yet there has been a roughly 30-year dry spell in antibiotic molecule discovery...
- [Sky Business News](https://www.recce.com.au/sky-business-news/) - Interview with Peter Switzer One of the worrying trends in hospitals are superbugs, raising question marks over the efficacy of antibiotics. Listed company Recce target is targeting this issue ..
- [Health & Biotech](https://www.recce.com.au/health-biotech/) - Why this 29-year-old investor took a six-figure stake in a $17m biotech company I prefer to have my money be working for me,” he tells Stockhead. “I don’t want it to be at the beck and call of Trump having...
- [Health & Biotech](https://www.recce.com.au/health-biotech-2/) - The biotech veteran chasing a billion-dollar pot of gold He was famously worth over $130 million — on paper at least — when he was running Chemeq, which blew itsel up a decade ago after he left.
- [Director Trades](https://www.recce.com.au/director-trades/) - A millennial director put his $100k into his own company rather than a house deposit It was millionaire’s row last week in small cap land, with four multi-million dollar trades and one that was pretty close...
- [Recce Pharmaceuticals locks](https://www.recce.com.au/recce-pharmaceuticals-locks/) - In US patent for synthetic antibiotic to target growing superbug problem Recce Pharmaceuticals (ASX: RCE) has locked-in a US patent for its broad-spectrum synthetic antibiotics, paving the way for the...
- [ASX:RCE](https://www.recce.com.au/asxrce/) - Recce Pharmaceuticals Ltd attracts $1.8 million as it moves toward human clinical trials Recce Pharmaceuticals Ltd (ASX:RCE) has raised about $1.8 million from sophisticated and institutional investors...
- [Recce Pharmaceuticals (ASX:RCE) secures sponsorship to attend BIO Korea 2023](https://www.recce.com.au/recce-pharmaceuticals-asxrce-secures-sponsorship-to-attend-bio-korea-2023/)
- [Recce Pharmaceuticals (ASX:RCE) appoints outpatient nurses from Ascott](https://www.recce.com.au/recce-pharmaceuticals-asxrce-appoints-outpatient-nurses-from-ascott/)
- [Recce Pharmaceuticals recruits outpatient nurses to drive “largest in Australia” diabetic foot infection clinical trial](https://www.recce.com.au/recce-pharmaceuticals-recruits-outpatient-nurses-to-drive-largest-in-australia-diabetic-foot-infection-clinical-trial/)
- [Recce Pharmaceuticals (ASX:RCE) gains ethics approval to expand phase I/II trial of R327](https://www.recce.com.au/recce-pharmaceuticals-asxrce-gains-ethics-approval-to-expand-phase-i-ii-trial-of-r327/)
- [Recce Pharmaceuticals receives Ethics Approval to expand R327 Faster Infusion, Phase I/II Clinical Trial](https://www.recce.com.au/recce-pharmaceuticals-receives-ethics-approval-to-expand-r327-faster-infusion-phase-i-ii-clinical-trial/)
- [Recce Pharmaceuticals lands ethics approval for expanded UTI studies](https://www.recce.com.au/recce-pharmaceuticals-lands-ethics-approval-for-expanded-uti-studies/)
- [Recce Pharmaceuticals (ASX:RCE) kicks off phase I/II UTI trial](https://www.recce.com.au/recce-pharmaceuticals-asxrce-kicks-off-phase-i-ii-uti-trial/)
- [Recce Pharmaceuticals — Gearing up for more R327 studies](https://www.recce.com.au/recce-pharmaceuticals-gearing-up-for-more-r327-studies/)
- [Recce Pharmaceuticals receives A$801,604 in R&D rebate advance](https://www.recce.com.au/recce-pharmaceuticals-receives-a801604-in-rd-rebate-advance/)
- [Recce Pharmaceuticals verifies positive Phase 1 data from R327 intravenous study](https://www.recce.com.au/recce-pharmaceuticals-verifies-positive-phase-1-data-from-r327-intravenous-study/)
- [Recce Pharmaceuticals (ASX:RCE) reports “positive” results from phase one R327 clinical trial](https://www.recce.com.au/recce-pharmaceuticals-asxrce-reports-positive-results-from-phase-one-r327-clinical-trial/)
- [Recce Pharmaceuticals (ASX:RCE) charges on with phase I/II UTI trial ahead of schedule](https://www.recce.com.au/recce-pharmaceuticals-asxrce-charges-on-with-phase-i-ii-uti-trial-ahead-of-schedule/)
- [Recce Pharmaceuticals awarded Australian patent for lead anti-infectives](https://www.recce.com.au/recce-pharmaceuticals-awarded-australian-patent-for-lead-anti-infectives/)
- [Recce Pharmaceuticals’ (ASX:RCE) new R327G shows positive response in treatment of antibiotic-resistant infections](https://www.recce.com.au/recce-pharmaceuticals-asxrce-new-r327g-shows-positive-response-in-treatment-of-antibiotic-resistant-infections/)
- [Recce Pharmaceuticals (ASX:RCE) concludes stage one analysis of phase I/II R327 topical trial for burn wounds](https://www.recce.com.au/recce-pharmaceuticals-asxrce-concludes-stage-one-analysis-of-phase-i-ii-r327-topical-trial-for-burn-wounds/)
- [Recce Pharmaceuticals (ASX:RCE) doses phase I/II patients in R327 diabetic foot infection trial](https://www.recce.com.au/recce-pharmaceuticals-asxrce-doses-phase-i-ii-patients-in-r327-diabetic-foot-infection-trial/)
- [Recce Pharmaceuticals — R327 progressing in rapid infusion study](https://www.recce.com.au/recce-pharmaceuticals-r327-progressing-in-rapid-infusion-study/)
- [Recce Pharmaceuticals (ASX:RCE) receives green light for higher dose in rapid infusion phase I/II UTI trial](https://www.recce.com.au/recce-pharmaceuticals-asxrce-receives-green-light-for-higher-dose-in-rapid-infusion-phase-i-ii-uti-trial/)
- [Recce Pharmaceuticals (ASX:RCE) paves its way to commercialisation with breakthrough antibiotic, R327](https://www.recce.com.au/recce-pharmaceuticals-asxrce-paves-its-way-to-commercialisation-with-breakthrough-antibiotic-r327/)
- [Recce Pharmaceuticals (ASX:RCE) completes cohort dosing in UTI rapid infusion trial](https://www.recce.com.au/recce-pharmaceuticals-asxrce-completes-cohort-dosing-in-uti-rapid-infusion-trial/)
- [Recce Pharmaceuticals advances anti-infective development and clinical trials in FY23](https://www.recce.com.au/recce-pharmaceuticals-advances-anti-infective-development-and-clinical-trials-in-fy23/)
- [Recce Pharmaceuticals raises further funds to progress trials from entitlement shortfall](https://www.recce.com.au/recce-pharmaceuticals-raises-further-funds-to-progress-trials-from-entitlement-shortfall/)
- [Global fund takes stake in Recce as synthetic antibiotic developer raises $11m](https://www.recce.com.au/global-fund-takes-stake-in-recce-as-synthetic-antibiotic-developer-raises-11m/)
- [Recce Pharmaceuticals raise to progress advanced anti-infective](https://www.recce.com.au/recce-pharmaceuticals-raise-to-progress-advanced-anti-infective/)
- [Recce Pharma says commercial potential of its anti-infectives is gaining recognition](https://www.recce.com.au/recce-pharma-says-commercial-potential-of-its-anti-infectives-is-gaining-recognition/)
- [Busiest quarter for Recce Pharmaceuticals: Cashed up for next phases of drug development](https://www.recce.com.au/busiest-quarter-for-recce-pharmaceuticals-cashed-up-for-next-phases-of-drug-development/)
- [Recce Pharmaceuticals accelerates R327 trial for UTI patients with faster infusion rate approval](https://www.recce.com.au/recce-pharmaceuticals-accelerates-r327-trial-for-uti-patients-with-faster-infusion-rate-approval-2/)
- [Recce Pharma welcomes approval for faster RECCE327 infusion rate](https://www.recce.com.au/recce-pharma-welcomes-approval-for-faster-recce327-infusion-rate/)
- [Recce Pharmaceuticals presents at Ord Minnett Healthcare Forum](https://www.recce.com.au/recce-pharmaceuticals-presents-at-ord-minnett-healthcare-forum/)
- [Recce Pharmaceuticals completes dosing of first subjects at faster infusion rate in RECCE® 327 clinical trial](https://www.recce.com.au/recce-pharmaceuticals-completes-dosing-of-first-subjects-at-faster-infusion-rate-in-recce-327-clinical-trial/)
- [Recce Pharmaceuticals doses first patients over 15 minutes in R327 UTI/urosepsis trial](https://www.recce.com.au/recce-pharmaceuticals-doses-first-patients-over-15-minutes-in-r327-uti-urosepsis-trial/)
- [Recce Pharmaceuticals wins Canadian patent for flagship anti-infectives](https://www.recce.com.au/recce-pharmaceuticals-wins-canadian-patent-for-flagship-anti-infectives/)
- [Engineering the future of antibiotics](https://www.recce.com.au/engineering-the-future-of-antibiotics/)
- [Antimicrobial resistance with Recce Pharmaceuticals](https://www.recce.com.au/antimicrobial-resistance-with-recce-pharmaceuticals/)
- [Recce Pharmaceuticals lead anti-infective R327 shows promise against deadly STD in latest animal study](https://www.recce.com.au/recce-pharmaceuticals-lead-anti-infective-r327-shows-promise-against-deadly-std-in-latest-animal-study/)
- [Recce Pharmaceuticals awarded $43.7 million Advanced Overseas Finding for synthetic anti-infective development program](https://www.recce.com.au/recce-pharmaceuticals-awarded-43-7-million-advanced-overseas-finding-for-synthetic-anti-infective-development-program/)
- [Recce Pharmaceuticals awarded A$11 million Advanced Overseas Finding for anti-viral R&D costs](https://www.recce.com.au/recce-pharmaceuticals-awarded-a11-million-advanced-overseas-finding-for-anti-viral-rd-costs/)
- [Recce secures Australia’s largest-ever $11m Advanced Overseas R&D Finding](https://www.recce.com.au/recce-secures-australias-largest-ever-11m-advanced-overseas-rd-finding/)
- [Recce Pharmaceuticals — Landmark commitment helps fund R&D costs](https://www.recce.com.au/recce-pharmaceuticals-landmark-commitment-helps-fund-rd-costs/)
- [Recce Pharmaceuticals higher on positive efficacy data in Murdoch Children’s Research Institute UTI study](https://www.recce.com.au/recce-pharmaceuticals-higher-on-positive-efficacy-data-in-murdoch-childrens-research-institute-uti-study/)
- [4 Biotech Executives Share Strategies Behind Successful Fund Raises](https://www.recce.com.au/4-biotech-executives-share-strategies-behind-successful-fund-raises/)
- [Revolutionary Antibiotic-Resistant Gonorrhea Treatment: A Possible Breakthrough with Recce 327](https://www.recce.com.au/revolutionary-antibiotic-resistant-gonorrhea-treatment-a-possible-breakthrough-with-recce-327/)
- [Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong](https://www.recce.com.au/recce-pharmaceuticals-to-expand-diabetes-foot-infection-trial-as-results-prove-strong/)
- [Recce Pharmaceuticals to expand diabetes foot infection trial as results prove strong](https://www.recce.com.au/recce-pharmaceuticals-to-expand-diabetes-foot-infection-trial-as-results-prove-strong-2/)
- [Recce Pharmaceuticals teams with leading Indonesian biomed company for anti-infective push](https://www.recce.com.au/recce-pharmaceuticals-teams-with-leading-indonesian-biomed-company-for-anti-infective-push/)
- [Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program](https://www.recce.com.au/recce-pharmaceuticals-establishes-strategic-partnership-in-south-east-asia-to-accelerate-clinical-program/)
- [Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances](https://www.recce.com.au/scrip-askswhat-does-2024-hold-for-biopharma-part-6-therapeutic-area-advances/)
- [Recce Pharmaceuticals wins safety approval to expand wound infection trial](https://www.recce.com.au/recce-pharmaceuticals-wins-safety-approval-to-expand-wound-infection-trial/)
- [Recce Pharmaceuticals leads the way in collaborative Anti-Infective research](https://www.recce.com.au/recce-pharmaceuticals-leads-the-way-in-collaborative-anti-infective-research/)
- [BioBoss Podcast - CEO James Graham](https://www.recce.com.au/bioboss-podcast-ceo-james-graham/)
- [Biotech around the World: The Low-Down on the Land Down Under](https://www.recce.com.au/biotech-around-the-world-the-low-down-on-the-land-down-under/)
- [Recce Pharmaceuticals secures AUD$11.18M from Endpoints Capital](https://www.recce.com.au/recce-pharmaceuticals-secures-aud11-18m-from-endpoints-capital/)
- [Recce Pharma (ASX:RCE) kicks-off dosing for next cohort of UTI trial](https://www.recce.com.au/recce-pharma-asxrce-kicks-off-dosing-for-next-cohort-of-uti-trial/)
- [Recce reaches testing milestone for UTI, Urosepsis antibiotic](https://www.recce.com.au/recce-reaches-testing-milestone-for-uti-urosepsis-antibiotic/)
- [Recce Pharmaceuticals hits major milestone in R327 clinical trial for UTI/urosepsis](https://www.recce.com.au/recce-pharmaceuticals-hits-major-milestone-in-r327-clinical-trial-for-uti-urosepsis/)
- [Recce reaches testing milestone for UTI, Uroseptis antibiotic](https://www.recce.com.au/recce-reaches-testing-milestone-for-uti-uroseptis-antibiotic/)
- [Recce Pharmaceuticals inks new patent for flagship drug in Israel](https://www.recce.com.au/recce-pharmaceuticals-inks-new-patent-for-flagship-drug-in-israel/)
- [Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel](https://www.recce.com.au/recce-gearing-up-for-indonesian-trials-us-dod-looking-at-r327-burn-gel/)
- [Recce Pharmaceuticals – Executive Interview](https://www.recce.com.au/recce-pharmaceuticals-executive-interview/)
- [Recce gearing up for Indonesian trials; US DOD looking at R327 burn gel](https://www.recce.com.au/recce-gearing-up-for-indonesian-trials-us-dod-looking-at-r327-burn-gel-2/)
- [Recce Pharmaceuticals selected to participate in UK Government Innovation Agency’s AMR Mission 2024](https://www.recce.com.au/recce-pharmaceuticals-selected-to-participate-in-uk-government-innovation-agencys-amr-mission-2024/)
- [Recce Pharmaceuticals up 6% on new antibiotic production milestone](https://www.recce.com.au/recce-pharmaceuticals-up-6-on-new-antibiotic-production-milestone/)
- [Recce weighs in on Q1 2024 as cash increases 100%](https://www.recce.com.au/recce-weighs-in-on-q1-2024-as-cash-increases-100/)
- [Recce Pharma picks up Chinese patent for anti-infective drugs](https://www.recce.com.au/recce-pharma-picks-up-chinese-patent-for-anti-infective-drugs/)
- [Recce Pharmaceuticals makes breakthrough in lung infection treatment with nebulised RECCE® 327](https://www.recce.com.au/recce-pharmaceuticals-makes-breakthrough-in-lung-infection-treatment-with-nebulised-recce-327/)
- [Recce Pharma heading closer to full efficacy data for flagship R327](https://www.recce.com.au/recce-pharma-heading-closer-to-full-efficacy-data-for-flagship-r327/)
- [Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market](https://www.recce.com.au/webinar-what-investors-should-know-about-what-it-takes-for-asx-listed-companies-to-get-medical-developments-to-market/)
- [Recce wraps up IV UTI trial with fastest infusion times yet; key safety review inbound](https://www.recce.com.au/recce-wraps-up-iv-uti-trial-with-fastest-infusion-times-yet-key-safety-review-inbound/)
- [Recce completes cohort dosing for Phase I/II UTI/Urosepsis Rapid Infusion Clinical Trial with fastest infusion times yet; key safety review inbound](https://www.recce.com.au/recce-completes-cohort-dosing-for-phase-i-ii-uti-urosepsis-rapid-infusion-clinical-trial-with-fastest-infusion-times-yet-key-safety-review-inbound/)
- [Recce Pharmaceuticals lands WHO Antibacterial Products in Clinical Development listing for RECCE® 327](https://www.recce.com.au/recce-pharmaceuticals-lands-who-antibacterial-products-in-clinical-development-listing-for-recce-327/)
- [Recce Starts Phase 2 R327 Gel trial for bacterial skin infections](https://www.recce.com.au/recce-starts-phase-2-r327-gel-trial-for-bacterial-skin-infections/)
- [Recce Pharmaceuticals reports positive data from Phase 1/2 UTI/urosepsis rapid infusion clinical trial of RECCE® 327](https://www.recce.com.au/recce-pharmaceuticals-reports-positive-data-from-phase-1-2-uti-urosepsis-rapid-infusion-clinical-trial-of-recce-327/)
- [Recce Pharmaceuticals granted US$2 million from US Department of Defense for RECCE® 327 Gel](https://www.recce.com.au/recce-pharmaceuticals-granted-us2-million-from-us-department-of-defense-for-recce-327-gel/)
- [Recce scores US$2M deal from US Department of Defense for burn wound infections gel](https://www.recce.com.au/recce-scores-us2m-deal-from-us-department-of-defense-for-burn-wound-infections-gel/)
- [Recce Pharmaceuticals more than doubles SPP target with A$4.4 million taking raise proceeds to A$12.4 million](https://www.recce.com.au/recce-pharmaceuticals-more-than-doubles-spp-target-with-a4-4-million-taking-raise-proceeds-to-a12-4-million/)
- [Recce Pharmaceuticals Delivers the Opening Address at World Antimicrobial Resistance Congress 2024](https://www.recce.com.au/recce-pharmaceuticals-delivers-the-opening-address-at-world-antimicrobial-resistance-congress-2024/)
- [Recce’s reconnaissance against superbug – infiltrate, eliminate, escape undetected](https://www.recce.com.au/recces-reconnaissance-against-superbug-infiltrate-eliminate-escape-undetected/)
- [Recce Pharmaceuticals Advances Antibiotic Development to Combat Antimicrobial Resistance](https://www.recce.com.au/recce-pharmaceuticals-advances-antibiotic-development-to-combat-antimicrobial-resistance/)

## Pages

- [Home](https://www.recce.com.au/) - Recce Pharmaceuticals (ASX: RCE) pioneers a New Class of Synthetic Anti-infectives to combat antibiotic-resistant superbugs.
- [Company Announcements](https://www.recce.com.au/company-announcements/) - Stay updated with Recce Pharmaceuticals' latest company announcements, investor updates, and corporate news in our fight against antibiotic resistance.
- [Pipeline](https://www.recce.com.au/pipeline/) - Recce’s pipeline targets the urgent need for innovative antibiotics with broad-spectrum activity against resistant and hard-to-treat infections.
- [Board of Directors and Management Team](https://www.recce.com.au/board-of-directors-and-management-team/) - Recce Pharmaceuticals includes a diverse Board of Directors and Management team who are experts in clinical research and business development.
- [Events and Presentations](https://www.recce.com.au/events-and-presentations/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) latest events, presentations, downloadable files and documents.
- [Intellectual Property](https://www.recce.com.au/intellectual-property/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) holds 4 patent families with 30+ patents, actively expanding and safeguarding its intellectual property for commercial and clinical advantages.
- [Burn Wound Infections](https://www.recce.com.au/burn-wound-infections/) - Addressing burn and wound infections with cutting-edge therapies, Recce Pharmaceuticals is at the forefront of developing treatments for resistant pathogens. Explore our approach to healing complex wounds.
- [Pre-clinical Indications](https://www.recce.com.au/pre-clinical-indications/) - RECCE® 327 (R327) is synthetically designed with a unique mechanism to combat deadly bacterial infections, including multi-drug resistant ESKAPE pathogens.
- [Diabetic Foot Infections](https://www.recce.com.au/diabetic-foot-infections/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) provides information on diabetic foot infections (DFI), the leading cause of nontraumatic foot amputations in diabetics
- [UTI](https://www.recce.com.au/uti/) - UTIs cause 30% of Sepsis (Urosepsis). R327's potential addresses this unmet medical need, offering therapy across the infectious disease journey.
- [FAQ](https://www.recce.com.au/faq/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) frequently asked questions covering general company information, Development pipeline, Clinical trials, and media relations.
- [About us](https://www.recce.com.au/about-us/) - Recce Pharmaceuticals is pioneering synthetic anti-infectives, with its lead compound, RECCE® 327, targeting a broad range of drug-resistant bacteria.
- [Share Price and Tools](https://www.recce.com.au/share-price-and-tools/) - Track the live share price of Recce Pharmaceuticals, with tools for investors including market cap, volume, and trading stats.
- [Contact us](https://www.recce.com.au/contact-us/) - Contact us at +61 (2) 9256 2505 or e-mail us on info@recce.com.au.
- [Product Candidates Overview](https://www.recce.com.au/product-candidates-overview/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) offers RECCE® 327 for bacterial and RECCE® 529 for viral infections, with a focus on 'difficult to treat' cases.
- [Manufacturing](https://www.recce.com.au/manufacturing/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) Sydney facility meets pharmaceutical standards and produces RECCE® 327 with 99.9% yield at 500 doses/hour, demonstrating quality and volume for clinical trials.
- [Corporate Governance](https://www.recce.com.au/corporate-governance/) - Recce Pharmaceuticals (ASX: RCE) and its Board of Directors prioritise effective, transparent, and ethical governance for efficient organisational management.
- [Mechanism of Action](https://www.recce.com.au/mechanism-of-action/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) anti-infectives are wholly synthetic and based on a patented polymeric structure and have been designed to overcome resistance.
- [Case Studies](https://www.recce.com.au/case-studies/) - Discover case studies on the clinical use of RECCE® 327 Gel (R327G) for antibiotic-resistant infections in patients with life-threatening conditions, under TGA SAS.
- [Acute Bacterial Skin and Skin-Structure Infections](https://www.recce.com.au/absssi/) - Discover Recce Pharmaceuticals' innovative approach to treating ABSSSI (acute bacterial skin and skin structure infections) with our breakthrough therapies targeting resistant bacteria. Learn how we're addressing this critical healthcare need.
- [Testing events](https://www.recce.com.au/testing-events/) - Events and Presentations Home Right Arrow-svg Investor & Media Right Arrow-svg Events and Presentations Play Play Play Play Play Play Play Play Play Play Play Play × Resources Fact Sheets & Posters 2026 Fact Sheet View Eye Icon-svg PDF 2026 MST Access Research Report View Eye Icon-svg PDF 2025 Edison Research Report View Eye Icon-svg
- [Sepsis](https://www.recce.com.au/sepsis/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) addresses Sepsis, a life-threatening infection response, highlighting the urgent need for effective treatments.
- [Shareholder Services](https://www.recce.com.au/shareholder-services/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) shareholder information. Should shareholders have any queries concerning their holding with Recce, please contact Automic.
- [In the News](https://www.recce.com.au/in-the-news/) - Recce Pharmaceuticals (ASX: RCE, FSE: R9Q) latest media coverage and articles. This includes articles from major media outlets and highlights of the company’s successes over the years.
- [Privacy Policy](https://www.recce.com.au/privacy-policy/) - Privacy Policy Home Right Arrow-svg Quick Links Right Arrow-svg Privacy Policy This Privacy Policy outlines how Recce Limited collects, uses and manages information obtained from visitors to this website. Recce views the personal privacy of visitors of the website as important and is committed to maintaining the security of personal information provided to Recce Limited
- [Add your title here](https://www.recce.com.au/add-your-title-here-2/)
- [Add your title here](https://www.recce.com.au/add-your-title-here/)
- [Disclaimer](https://www.recce.com.au/disclaimer/) - Disclaimer Home Right Arrow-svg Quick Links Right Arrow-svg Disclaimer This website (‘www.recce.com.au’) is the property of Recce Limited (‘Recce’ or the ‘Company’) and visitors to the site are bound by the following terms and conditions. The information contained in this website has been prepared solely for the purpose of providing general information. The Company has

## Categories

- [In the News](https://www.recce.com.au/category/in-the-news/)